SCHEMBL905356

SCHEMBL905356

CCOC(=O)CN1CCN(c2cc(-c3ccccc3C)c(C(=O)NC)cn2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 2/20 0.44
SMO Q99835 3/20 0.44
CYP11B2 P19099 1/20 0.42
BACE1 P56817 1/20 0.41
ITGB2 P05107 1/20 0.40
ICAM1 P05362 1/20 0.40
ITGAL P20701 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
POLB P06746 1/20 0.39
DRD2 P14416 2/20 0.38
DRD4 P21917 2/20 0.38
HSD17B10 Q99714 2/20 0.38
PARP1 P09874 1/20 0.38
PARP2 Q9UGN5 1/20 0.38
DRD3 P35462 1/20 0.38
SLC6A4 P31645 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38
HBB P68871 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL905365 0.86 TACR1 (0.49) TACR1SMOCYP11B2DRD2DRD4
SCHEMBL6286992 0.83 PTPN11 (0.50) KMT2AMEN1POLBLMNASMN1; SMN2
SCHEMBL905364 0.83 TACR1 (0.57) TACR1SMOKMT2AMEN1L3MBTL1
SCHEMBL7137826 0.81 TACR1 (0.47) TACR1SMOL3MBTL1ALDH1A1
SCHEMBL905377 0.80 TACR1 (0.45) TACR1SMOL3MBTL1
SCHEMBL905379 0.80 CYP1A2 (0.54) TACR1ALDH1A1MAPT
SCHEMBL905329 0.78 CKS1B (0.48) TACR1SMOKMT2AMEN1SMN1; SMN2
SCHEMBL905355 0.78 TACR1 (0.77) TACR1
SCHEMBL4672291 0.77 TACR1 (0.43) TACR1SMOL3MBTL1ALDH1A1
SCHEMBL18791038 0.75 CYP11B2 (0.64) SMOCYP11B2BACE1ITGB2ICAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1394150-B1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists HOFFMANN LA ROCHE (CH) 2011-01-19 EP disclosed
EP-1394150-A1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 2004-03-03 EP disclosed
US-20020091265-A1 4-phenyl-pyridine derivatives BOS MICHAEL (CA) 2002-07-11 US disclosed
US-6297375-B1 4-phenyl-pyridine derivatives HOFFMANN-LA ROCHE INC. 2001-10-02 US disclosed
EP-1035115-A1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 2000-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091265-A1 4-phenyl-pyridine derivatives CBR1, CBR3, HCCS TACR1 534/4885SMO 3742/4885CYP11B2 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.